EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Impact of Organ‐Specific Severe Immune‐Related Adverse Events on Long‐Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5‐Year Multicenter Multistate Analysis

Yoshihiko Tasaki iD, Kazumasa Sato, Shuzo Hamamoto iD, Yosuke Sugiyama iD, Hiroaki Ikoma, Kengo Kawase iD, Hiroko Suzuki, Yusuke Noda, Masayuki Usami iD, Yohei Tsubouchi, Ryuga Kato, Takuya Sakata iD und 8 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72410 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Yoshihiko Tasaki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune‐related adverse events (irAEs) frequently occur during combination immune checkpoint inhibition. However, their prognostic impact may vary according to organ involvement and severity. In this study, we exploratorily evaluated whether severe non‐endocrine irAEs represent a temporally distinct and prognostically unfavorable clinical phenotype in patients with metastatic renal cell carcinoma (mRCC) treated with ipilimumab plus nivolumab. Patients and Methods We analyzed 63 patients with mRCC treated with ipilimumab plus nivolumab who were followed for at least 5 years. Patients were categorized into non‐irAE, non‐severe + severe endocrine irAE, and severe non‐endocrine irAE groups. Overall survival (OS) was assessed. Multistate modeling was used to evaluate the transitions between treatment, irAE occurrence, and death. Landmark analyses were performed at 8 and 12 weeks to address immortal time bias.

Results

The severe non‐endocrine irAE group was associated with inferior OS. The multistate analysis revealed a potentially increased risk of direct transition from ipilimumab plus nivolumab to death in the severe non‐endocrine irAE group. A significantly higher proportion of patients in the severe non‐endocrine irAE group experienced irAEs within 30 days. No significant association was observed in the 8‐ and 12‐week landmark analyses.

Conclusion

In this exploratory retrospective study, severe non‐endocrine irAEs showed an association with early onset and potentially unfavorable clinical outcomes in patients with mRCC receiving ipilimumab plus nivolumab. Given the limited sample size, these findings should be interpreted cautiously and require confirmation in larger independent cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansFemaleIpilimumabMaleNivolumabMiddle AgedAgedPrognosisRetrospective Studies

Stichwörter der Autor:innen

immune‐related adverse eventsimmunotherapyipilimumabmetastatic renal cell carcinomamultistate modelingnivolumabprognosis

Substanzen

IpilimumabNivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
  • Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
  • Department of Urology, Kainan Hospital, Yatomi, Aichi, Japan.
  • Department of Urology, Anjo Kosei Hospital, Anjo, Aichi, Japan.
  • Department of Urology, Toyota Kosei Hospital, Toyota, Aichi, Japan.
  • Department of Urology, Konan Kosei Hospital, Konan, Aichi, Japan.

ORCID-Profile: Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Kengo Kawase, Masayuki Usami, Takuya Sakata, Yoshihisa Mimura, Takashi Nagai, Rei Unno, Taku Naiki, Takahiro Yasui, Yoko Furukawa-Hibi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Tasaki, Y., Sato, K., Hamamoto, S., Sugiyama, Y., Ikoma, H., Kawase, K., Suzuki, H., Noda, Y., Usami, M., Tsubouchi, Y., Kato, R., Sakata, T., Tomita, M., Mimura, Y., Nagai, T., Unno, R., Etani, T., Naiki, T., Yasui, T., & Furukawa-Hibi, Y. (2026). Impact of Organ‐Specific Severe Immune‐Related Adverse Events on Long‐Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5‐Year Multicenter Multistate Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.72410

Vancouver

Tasaki Y, Sato K, Hamamoto S, Sugiyama Y, Ikoma H, Kawase K, et al. Impact of Organ‐Specific Severe Immune‐Related Adverse Events on Long‐Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5‐Year Multicenter Multistate Analysis. Cancer Medicine. 2026. doi:10.1002/cam4.72410

BibTeX
@article{Tasaki2026,
  author = {Tasaki, Yoshihiko and Sato, Kazumasa and Hamamoto, Shuzo and Sugiyama, Yosuke and Ikoma, Hiroaki and Kawase, Kengo and Suzuki, Hiroko and Noda, Yusuke and Usami, Masayuki and Tsubouchi, Yohei and Kato, Ryuga and Sakata, Takuya and Tomita, Misato and Mimura, Yoshihisa and Nagai, Takashi and Unno, Rei and Etani, Toshiki and Naiki, Taku and Yasui, Takahiro and Furukawa-Hibi, Yoko},
  title = {Impact of Organ‐Specific Severe Immune‐Related Adverse Events on Long‐Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5‐Year Multicenter Multistate Analysis},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72410}
}
Kostenlos starten →